Fig 1: Evaluating apolipoproteins as potential biomarkers for sporadic ALS. (A) Measurement of neurofilament light chain (NfL) in sporadic ALS (N = 32) and healthy control (N = 32) serum. Data represent mean and S.E.M. as error bars. Group differences were assessed using Welch's two‐sample t‐test. (B) Pearson correlation of NfL with age in healthy controls. (C) Receiver operating characteristic (ROC) curve and area under the curve (AUC) value for NfL. (D) ROC curves and AUC values for apolipoproteins. (E) ROC curves and AUC values for the apoAII/apoE and apoAII/apoB ratios. (F) Pearson correlation analysis of NfL with apolipoproteins.
Fig 2: Analysis of inter‐relationship among apolipoproteins in amyotrophic lateral sclerosis serum. (A) Analysis of the apoB/apoAI ratio in sporadic ALS (N = 32) and healthy control (N = 32) serum. The red line denoting the threshold value of 1.0. Group differences were assessed using Welch's two‐sample t‐test. (B) Analysis of various ratios in ALS and control serum. Data represent mean and S.E.M. as error bars. (C) Pearson correlation coefficient (r) for all possible combinations of apolipoproteins. (D) Analysis of correlation between apoAI and apoAII. (E). Analysis of correlation between apoCII and apoCIII. (F) Analysis of correlation between apoE and apoCII. (G) Analysis of correlation between apoB and apoCIII.
Supplier Page from Abcam for Human Apolipoprotein AII ELISA Kit, Fluorescent